Besides its core business Finecure Pharmaceuticals has also forayed into the therapeutic segments of cardiovascular and diabetology. The ‘Neocardiabcare’ Division of Finecure Pharmaceuticals Ltd, Flagship Company of the Finecure Group of companies was launched in 2014 specifically with the purpose of manufacturing of formulations under cardiovascular and anti-diabetics therapeutic segments, to add to its parent company’s vast list of pharma products in various remedial sectors.
Our prime motivation for commencing this Division came from the ever increasing incidence of cardiovascular diseases that are escalating in India, especially among the young at an alarming rate. Cardiovascular disease, including diabetes is the leading cause of death across the world. In India it is on the verge of becoming an epidemic.
We at Finecure we are aware that India is a young country and these diseases are afflicting are young population and that they need to be kept in check. It is seen that owing to various factors especially unhealthy eating habits and a sedentary lifestyle more people in their 20s, 30s and 40s have been getting heart ailments. The problem is that heart disease at a prime age takes away the productive years from young India. Socio-economic burden on person, family as well as nation is very high.
Finecure is committed to help address this alarming growth and hence have commenced a dedicated “NEOCARDIABCARE” unit with an aim to create innovative medicines to combat the rapid increase of these lifestyle diseases and help humanity lead longer, healthier, happier lives.
The ‘Neocardiabcare’ Division is visioned to address the alarming increase of lifestyle ailments like hypertension and cardiometabolic diseases. Our foremost aim and mission is to combat the rapid increase of these lifestyle diseases and help humanity to lead longer, healthier and happier lives. To this end we are committed to identify and meet the unmet medical needs of this specific segment and speedily supply products that best reflect their requirements.
The ‘Neocardiabcare’ Division has crafted its own niche in the market and the trust on the effectiveness, safety and worth of its formulations and its availability and affordability has enabled it to reach the pinnacle of success and accomplishment. We are determined to achieve our goal of becoming a force in affordable, qualitative and reachable cardiac and diabetes healthcare solutions. We are very well positioned to build upon the positive momentum we have generated since our launch four years ago.
Our foremost goal and duty at ‘Neocardiabcare’ Division is to combat the rapid increase of these lifestyle diseases and help humanity to lead longer, healthier and happier lives. To this end we are committed to identify and meet the unmet medical needs of this specific segment and speedily supply products that best reflect their requirements. The ‘Neocardiabcare’ Division of Finecure Pharmaceuticals Ltd has crafted its own niche in the market and the trust on the effectiveness, safety and worth of its formulations and its availability and affordability has enabled it to reach the pinnacle of success and accomplishment.
We are very well positioned to build upon the positive momentum we have generated since our launch. We remain focused on our mission of advancing patient care through the delivery of high-quality yet affordable pharmaceutical products, explicitly for lifestyle diseases like heart ailments, hypertension and diabetes.
We will continue to hone our technologies even further, bringing about new developments and better and more effective products to ensure that we contribute to build an even healthier society and a healthier nation.
Our formulations include Anticoagulants Antiplatelet medications, Beta blockers, Calcium channel blockers and Diuretics etc. We manufacture a wide range of Cardiac & Diabetic medicines with combinations of high-quality composition drugs like Amlodipine, Atenolol, Glimepiride, Ramipril, Telmisartan, Metformin, Atorvastatin Cilnidipine etc.
